Loading...

Home
Stock
HOTH

HOTH Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

0.586

Open

0.544

VWAP

0.56

Vol

1.01M

Mkt Cap

10.75M

Low

0.532

Amount

566.66K

EV/EBITDA(TTM)

--

Total Shares

19.13M

EV

4.50M

EV/OCF(TTM)

--

P/S(TTM)

--

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Show More

Events Timeline

(ET)

2026-04-01

14:00:00

Hoth Therapeutics to Offer 2.86M Shares at $0.70 Each

2026-04-01

08:20:00

Hoth Therapeutics Reports Positive Clinical Results for HT-001

2026-03-31 (ET)

2026-03-31

08:10:00

Hoth Therapeutics Secures Chinese Patent Valid Until 2039

2026-03-24 (ET)

2026-03-24

08:30:00

Hoth Therapeutics Reports Positive Clinical Data for HT-001

2026-03-10 (ET)

2026-03-10

08:20:00

Hoth Therapeutics Announces New Female-Specific Metabolic Disease Study Results

2026-02-24 (ET)

2026-02-24

16:30:00

Hoth Therapeutics Expands CLEER-001 Clinical Trial

2026-02-12 (ET)

2026-02-12

08:40:00

Hoth Therapeutics Receives Patent Allowance for Allergy Treatment

2026-02-10 (ET)

2026-02-10

08:40:00

Hoth Therapeutics Releases Compelling GDNF Preclinical Data Showing Significant Weight Loss Effects

2026-01-22 (ET)

2026-01-22

08:30:00

Hoth Therapeutics Reports Positive Interim Results from CLEER-001 Trial

News

PRnewswire

04-02PRnewswire

PinnedHoth Therapeutics Closes Registered Direct Offering

Offering Size: Hoth Therapeutics successfully closed a registered direct offering of 2,857,144 shares of common stock at an offering price of $0.70 per share, which is expected to generate approximately $2 million in gross proceeds, enhancing the company's liquidity to support future R&D activities.
Placement Details: In conjunction with this offering, the company issued unregistered warrants to purchase up to 2,857,144 shares of common stock at an exercise price of $0.85 per share, which is anticipated to provide additional funding support and further strengthen its capital structure.
Use of Proceeds: Hoth Therapeutics indicated that the net proceeds will be utilized for general corporate purposes, including working capital, which will help the company maintain competitiveness in clinical-stage biopharmaceutical development and drive innovation.
Compliance Statement: The offering complies with Section 4(a)(2) of the Securities Act of 1933, ensuring that the issuance of unregistered warrants and related shares adheres to applicable laws and regulations, thereby mitigating legal risks associated with the financing.

NASDAQ.COM

04-02NASDAQ.COM

Hoth Therapeutics Secures $2 Million Financing Through Share Offering

Financing Agreement: Hoth Therapeutics has announced a definitive agreement to sell 2.85 million shares at $0.70 each, expecting gross proceeds of $2 million, which will be allocated for general corporate purposes and working capital.
Private Placement Details: Concurrently, the company issued unregistered warrants to purchase up to 2.86 million shares at an exercise price of $0.85, potentially raising approximately $2.4 million if fully exercised, thereby enhancing financial flexibility.
Transaction Timeline: The closing of this offering is anticipated around April 2, 2026, with the unregistered warrants becoming exercisable six months post-issuance and expiring in five and a half years, indicating the company's strategic planning for future funding operations.
Market Performance Review: Hoth Therapeutics' stock has traded between $0.50 and $2.11 over the past year, closing at $0.54 on Wednesday, down 34.86% from the previous trading day, reflecting market caution regarding the company's outlook.

Newsfilter

04-01Newsfilter

Hoth Therapeutics Announces Stock Offering and Warrants Sale

Offering Details: Hoth Therapeutics announced a direct offering of 2,857,144 shares at $0.70 each, expecting gross proceeds of approximately $2 million, which will be utilized for general corporate purposes including working capital.
Warrant Issuance: Concurrently, the company issued unregistered warrants to purchase the same number of shares at an exercise price of $0.85, potentially raising an additional $2.4 million if fully exercised, enhancing financial flexibility.
Transaction Arrangement: The offering is managed by H.C. Wainwright & Co. as the exclusive placement agent, with the closing expected around April 2, 2026, contingent upon customary closing conditions being met.
Registration Statement Background: This stock offering is conducted under a shelf registration statement filed in 2015, demonstrating the company's compliance and transparency in capital markets, which is likely to bolster investor confidence.

PRnewswire

04-01PRnewswire

Hoth Therapeutics Completes Stock Offering Agreement

Stock Offering Details: Hoth Therapeutics announced the issuance of 2,857,144 shares of common stock at $0.70 per share, with expected gross proceeds of approximately $2 million, which will be used for general corporate purposes, including working capital.
Warrant Issuance: Concurrently, the company issued unregistered warrants allowing the purchase of the same number of common shares at an exercise price of $0.85 per share, potentially generating an additional $2.4 million if fully exercised.
Transaction Arrangement: The offering is being managed by H.C. Wainwright & Co. as the exclusive placement agent, with the closing expected around April 2, 2026, subject to customary closing conditions.
Registration Statement Background: This stock offering is based on a Form S-3 registration statement filed in 2015, which became effective on December 4, 2025, ensuring compliance and transparency in the issuance process.

PRnewswire

04-01PRnewswire

Hoth Therapeutics Reports Positive Clinical Results for HT-001 Program

Significant Clinical Outcomes: In the interim analysis of the HT-001 program, over 65% of patients reported meaningful reductions in pain and itching, indicating the therapy's potential to significantly enhance the quality of life for patients suffering from dermatologic toxicities.
Zero Treatment Disruption: Importantly, no patients required dose reductions or discontinuation of their EGFR inhibitor therapy while receiving HT-001, highlighting its ability to manage dermatologic side effects without interfering with life-saving cancer treatments.
Pharmacokinetic Advantage: The pharmacokinetic analysis of HT-001 demonstrated approximately 99% lower systemic exposure compared to FDA-approved oral therapies, supporting its targeted delivery profile designed to maximize local efficacy while minimizing systemic side effects.
International Expansion Plans: Hoth Therapeutics has received regulatory approval in Hungary, enabling the expansion of the Phase 2 clinical trial into Europe, with additional approvals anticipated in Spain and Poland, further accelerating patient enrollment and data generation.

PRnewswire

03-26PRnewswire

Hoth Therapeutics Launches AI Drug Development Platform OpenClaw™

AI-Driven Drug Discovery: Hoth Therapeutics' launch of the OpenClaw™ platform integrates clinical and preclinical data in real-time, accelerating the drug discovery process and is expected to significantly enhance development efficiency and success probability, thereby boosting the company's competitiveness in the biopharmaceutical sector.
Modular Design Advantage: The modular design of OpenClaw™ allows seamless deployment across multiple indications, including dermatology, oncology, and inflammatory diseases, standardizing workflows and increasing reproducibility, which further enhances Hoth's R&D capabilities across various therapeutic areas.
Strategic Shift: The launch of this platform marks a strategic shift for Hoth at the intersection of biotechnology and artificial intelligence, leveraging advanced analytics to drive innovation and pipeline expansion, thereby strengthening the company's position in the rapidly evolving biopharmaceutical market.
CEO Outlook: Hoth's CEO Robb Knie stated that OpenClaw™ will enhance the company's decision-making capabilities and data value extraction, marking the entry into a new phase of execution, with expectations to accelerate product development and market responsiveness.

Valuation Metrics

The current forward P/E ratio for Hoth Therapeutics Inc (HOTH.O) is 0.00, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess Hoth Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.49

Current PE

0.00

Overvalued PE

-0.72

Undervalued PE

-2.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.40

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.69

Undervalued EV/EBITDA

-1.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

possible longs in short term

Intellectia · 53 candidates

Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Floating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Nektar Therapeutics

1.44B

Biomx Inc

9.77M

Energy Services Of America Corp

231.56M

Scworx Corp

4.00M

SIFCO Industries Inc

54.64M

Karyopharm Therapeutics Inc

163.69M

stocks between $1.00 and $1.10

Intellectia · 54 candidates

Price: $1.00 - $1.10

Ticker

Name

Market Cap$

Adagio Medical Holdings Inc

22.87M

Heidmar Maritime Holdings Corp

61.90M

CCSC Technology International Holdings Ltd

4.15M

Auddia Inc

3.35M

Estrella Immunopharma Inc

42.45M

CytoMed Therapeutics Ltd

11.15M

list of small cap stock symbol bull traps

Intellectia · 420 candidates

Market Cap: <= 2.00BRelative Vol: >= 0.500Moving Average Relationship: PriceCrossAboveMA20, PriceCrossDownMA20

Ticker

Name

Market Cap$

PAVmed Inc

11.92M

Namib Minerals

121.31M

Roma Green Finance Ltd

143.55M

Lucid Diagnostics Inc

148.14M

Marygold Companies Inc

53.85M

Revelation Biosciences Inc

4.98M

penny stock to buy tomorrow?

Intellectia · 19 candidates

Price: <= $5.00Relative Vol: >= 1.50Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 15

Ticker

Name

Market Cap$

Banco Bradesco SA

39.45B

Satellogic Inc

486.33M

American Resources Corp

448.43M

Aditxt Inc

2.59M

New Fortress Energy Inc

441.06M

Lucid Diagnostics Inc

148.14M

what penny stocks will go up this week

Intellectia · 41 candidates

Market Cap: <= 300.00MPrice: <= $5.00Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Boxlight Corp

1.73M

Pineapple Financial Inc

1.90M

Aditxt Inc

2.59M

Freight Technologies Inc

2.66M

Integrated Media Technology Ltd

3.15M

Twin Vee PowerCats Co

3.51M

which penny stock to buy today?

Intellectia · 19 candidates

Price: <= $5.00Relative Vol: >= 1.50Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 15

Ticker

Name

Market Cap$

Hoth Therapeutics Inc

16.29M

Lucid Diagnostics Inc

148.14M

Aditxt Inc

2.59M

New Fortress Energy Inc

441.06M

Energy of Minas Gerais Co

5.98B

So-Young International Inc

305.89M

top 10 penny stocks to invest in today

Intellectia · 545 candidates

Price: <= $5.00Weekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Global Interactive Technologies Inc

6.25M

Namib Minerals

121.31M

Smart Logistics Global Ltd

75.44M

Freight Technologies Inc

2.66M

Lisata Therapeutics Inc

35.55M

Roma Green Finance Ltd

143.55M

increase the range for $0.12-$1.20

Intellectia · 13 candidates

Price: $0.12 - $1.20Volume: >= 3,000,000Relative Vol: >= 1.50List Exchange: XNAS

Ticker

Name

Market Cap$

Humacyte Inc

189.14M

Lucid Diagnostics Inc

148.14M

Oncolytics Biotech Inc

125.90M

Electra Battery Materials Corporation

97.40M

Cue Biopharma Inc

34.28M

Surgepays Inc

25.72M

Whales Holding HOTH

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Hoth Therapeutics Inc (HOTH) stock price today?

The current price of HOTH is 0.5619 USD — it has increased 2.56

What is Hoth Therapeutics Inc (HOTH)'s business?

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

What is the price predicton of HOTH Stock?

Wall Street analysts forecast HOTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOTH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hoth Therapeutics Inc (HOTH)'s revenue for the last quarter?

Hoth Therapeutics Inc revenue for the last quarter amounts to -2.60M USD, increased 9.31

What is Hoth Therapeutics Inc (HOTH)'s earnings per share (EPS) for the last quarter?

Hoth Therapeutics Inc. EPS for the last quarter amounts to -2150385.00 USD, decreased

How many employees does Hoth Therapeutics Inc (HOTH). have?

Hoth Therapeutics Inc (HOTH) has 2 emplpoyees as of April 04 2026.

What is Hoth Therapeutics Inc (HOTH) market cap?

Today HOTH has the market capitalization of 10.75M USD.